Theme

Tumor-type
specific Sessions

Session Title

Medulloblastoma(clinical)

Presentation
No.

Abstract
No.

Lecture title

MEDC-IS-01

SPKR-57

Medulloblastoma – Biology informs Clinical Outcome

MEDC-IS-02

SPKR-42

MEDC-O-03

MBCL-16

MEDC-O-04

MBCL-15

MEDC-O-05

MBCL-08

MEDC-O-06

SpeakerCountryAmar Gajjar

USA

Lorena Baroni

Argentina

Sarah Leary

USA

Jeff Michalski

USA

Integrative molecular analysis of patient-matched diagnostic and relapsed medulloblastomas

Rahul Kumar

USA

MBCL-34

Efficacy of methotrexate (MTX) according to molecular sub-type in young children withmedulloblastoma (MB): A report from Children’s Oncology Group Phase III trial ACNS0334

Claire Mazewski

USA

MEDC-P-07

MBCL-21

Germline elongator mutations in sonic hedgehog medulloblastoma

Giles Robinson

USA

MEDC-P-08

MBCL-06

MEDC-P-09

MBCL-07

MEDC-P-10

MBCL-29

MEDC-P-11

MBCL-36

MEDC-P-12

MBCL-02

MEDC-P-13

MBCL-25

MEDC-P-14

MBCL-09

MEDC-P-15

MBCL-11

MEDC-P-16

MBCL-03

MEDC-P-17

MBCL-24

MEDC-P-18

MBCL-28

MEDC-P-19

MBCL-31

MEDC-P-20

MBCL-51

MEDC-P-21

MBCL-26

MEDC-P-22

MBCL-52

MEDC-P-23

MBCL-12

MEDC-P-24

MBCL-19

MEDC-P-25

MBCL-20

MEDC-P-26

MBCL-43

MEDC-P-27

MBCL-48

MEDC-P-28

MBCL-01

MEDC-P-29

MBCL-05

MEDC-P-30

MBCL-17

MEDC-P-31

MBCL-22

MEDC-P-32

MBCL-23

MEDC-P-33

MBCL-38

MEDC-P-34

Bridging the treatment gap in infant medulloblastoma: Subgroup and subtype specificoutcomes of a globally feasible regimen
Efficacy of carboplatin given concomitantly with radiation and isotretinoin as a pro-apoptotic
agent in maintenance therapy in high-risk medulloblastoma: A report from the Children’sOncology Group
Impact of molecular subgroups on outcomes following radiation treatment randomizations foraverage risk medulloblastoma: a planned analysis of Children's Oncology Group (COG)
ACNS0331

Risk stratification improvement of the HIT2000 and I-HIT-MED cohorts using molecular
Martin Mynarek
subtypes I-VIII of Group 3/4 medulloblastomas
Non-metastatic medulloblastoma of early childhood: Results from the prospective clinical trial
Martin Mynarek
HIT-2000 and an extended validation cohort
Phase I/II study of sequential high-dose chemotherapy with stem cell support in children
Christelle Dufour
younger than 5 years of age with high-risk medulloblastoma.
How to increase survival in 7 to 10% of patients with average-risk medulloblastoma without
Nicholas Gottardo
new therapies: early prospective neuroradiology screening experience from the Children’s
Oncology Group
Role of preoperative chemotherapy in metastatic medulloblastoma: a comparative study in 92
Léa Guerrini-Rousseauchildren
Pilot study of a surgery and chemotherapy-only approach in the upfront therapy of children
Kenneth Cohenwith Wnt-positive standard risk medulloblastoma: Updated outcomes
Isolated M1 metastases in pediatric medulloblastoma: is postoperative radiotherapy followed
Denise Obrecht
by maintenance chemotherapy superior to postoperative sandwich-chemotherapy andradiotherapy?
Time to radiotherapy impacts survival in pediatric and adolescent non-metastatic
Martin Mynarek
medulloblastoma treated by upfront radiotherapy – A report from the HIT 2000 trial
Results of high-dose thiotepa, carboplatin and etoposide with autologous hematopoietic stemAsmik Gevorgiancell transplantation for patients with recurrent medulloblastoma
Can young children with relapsed medulloblastoma be salvaged after initial irradiation-sparing
Craig Erker
approaches?
Long-term follow-up results of reduced dose craniospinal radiotherapy and tandem high-dose
Ji Won Lee
chemotherapy in patients with high-risk medulloblastoma
Treatment results among 106 patients with medulloblastoma of molecular subgroup 3

Olga Zheludkova

Post-autologous hematopoietic cell transplantation (AuHCT) practices for young children withScott Covenmalignant brain tumors
Factors associated with longer survival after first recurrence in medulloblastoma by molecular
Murali Chintagumpala
subgroup after risk-based initial therapy
Endocrine profile after medulloblastoma treatment
Molecular signatures and tumor infiltrating immunological cells associated with Asian
medulloblastoma patient survival
Chemotherapy strategies for young children newly diagnosed with desmoplastic/extensive
nodular medulloblastoma up to the era of molecular profiling – a comparative outcomesanalysis of prospective multi-center European and North American trials

Germany
FranceAustralia
FranceUSA
Germany
Germany
RussiaCanadaKorea
RussiaUSAUSA

Martin English

UK

Kung-Hao LiangTaiwan

Jonathan Finlay

USA

Detection of somatic mutations by using RNA-Seq data in childhood medulloblastoma and its
Tai-Tong Wongpotential clinical application: A cohort series of 52 cases study in Taiwan
Recurrent medulloblastoma – long-term survival with a “MEMMAT” based antiangiogenic
approach
Outcomes of treatment based on the St. Jude medulloblastoma-96 regimen for Japanesechildren with medulloblastoma
Methylation profiling of pediatric medulloblastoma in Saudi Arabia in a clinical setting permits
sub-classification and reveals new outcome predictions
Treatment of children with medulloblastoma without metastatic involvement in the age groupolder than 3 years: results of intercenter trial
Metastatic medulloblastoma can be cured without excision of the primary tumor: A single
center experience.
Efficacy of double-conditioning regimen comprising thiotepa and melphalan for relapsed
medulloblastoma – a single institution experience
Preliminary analysis of treatment-related toxicities during induction chemotherapy for patientson the Head Start 4 trial

Germany

TaiwanIrene Slavc

Austria

Junya Fujimura

JapanNahla Mobark

Saudi Arabia

Andrey Levashov

RussiaRina Dvir

IsraelKai Yamasaki

JapanVibhuti Agarwal

USA

Unusual extraneural metastasis of pediatric embryonal tumors: two case reports

Ashley Plant

USAMBCL-04

5 – azacytidine in treatment of children with de novo and relapsed metastatic
medulloblastoma: results of intercenter pilot study

Andrey Levashov

Russia

MEDC-P-35

MBCL-35

Salvage radiation therapy for progressive and/or relapsed pediatric medulloblastoma

Muhammad BaigUSA

MEDC-P-36

MBCL-10

Local recurrence and survival outcomes of medulloblastoma (MB) in adolescent and young
adult patients (AYA)

Warissara RongthongThailand

MEDC-P-37

MBCL-13

Correlation of histopathology, chromosomal microarray, and NanoString based 22-gene assay
Girish Dhall
for medulloblastoma subgroup assignment on “Head Start” 4 clinical trial

MEDC-P-38

MBCL-18

MEDC-P-39

MBCL-32

MEDC-P-40

MBCL-46

MEDC-P-41

MBCL-50

MEDC-P-42

MBCL-33

MEDC-P-43

MBCL-14

MEDC-P-44

MBCL-41

MEDC-P-45

MBCL-27

MEDC-P-46
MEDC-P-47

Analysis of DNA methylation profiles of pediatric medulloblastomas: experience at theBambino Gesù Children’s HospitalHigh-dose chemotherapy with stem cell rescue for recurrent previously irradiatedmedulloblastoma
Treatment of recurrent wingless-activated medulloblastoma (Wnt-MB) incorporating marrowablative thiotepa and carboplatin chemotherapy (HDCx) and autologous hematopoietic
progenitor cell rescue (AuHPCR): a dual report
Dismal outcome of high risk medulloblastoma treated with chemotherapy first approach in
Malaysia
Rare pulmonary toxicity in three medulloblastoma patients undergoing antiangiogenic
metronomic combination therapy
A study of low-dose craniospinal radiation therapy in patients with newly diagnosed averagerisk medulloblastoma
Lymphohematopoietic toxicity identified in patients with medulloblastoma receiving
craniospinal irradiation

USAEvelina Miele

Italy

Ekaterina Salnikova

RussiaMicah HarrisUSA

Shiao Wei Quah

Malaysia

Alicia Lenzen

USAAaron Mochizuki

USA

Atsuko Watanabe

Japan

Association of medulloblastoma with Charcot-Marie-Tooth disease

Kenichiro Watanabe

Japan

MBCL-30Novel SMO mutation in desmoplastic/nodular medulloblastoma: a case report

Avery WrightUSA

MBCL-37

Chemotherapy strategies for young children newly diagnosed with classic (ClMB) oranaplastic/large cell (A/LCMB) medulloblastoma up to the era of molecular profiling – acomparative outcomes analysis

Jonathan FinlayUSA